VectorGlobal IAG Inc. Takes $9.20 Million Position in McKesson Corporation $MCK

VectorGlobal IAG Inc. acquired a new position in McKesson Corporation (NYSE:MCK) during the 1st quarter, HoldingsChannel.com reports. The firm acquired 10,627 shares of the company’s stock, valued at approximately $9,196,000. McKesson makes up 2.4% of VectorGlobal IAG Inc.’s holdings, making the stock its 16th largest holding.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Meiji Yasuda Asset Management Co Ltd. increased its stake in McKesson by 0.5% in the 4th quarter. Meiji Yasuda Asset Management Co Ltd. now owns 2,262 shares of the company’s stock worth $1,855,000 after purchasing an additional 11 shares during the period. Investment Research Partners LLC boosted its stake in shares of McKesson by 0.7% during the fourth quarter. Investment Research Partners LLC now owns 1,624 shares of the company’s stock valued at $1,332,000 after purchasing an additional 11 shares during the period. IHT Wealth Management LLC boosted its stake in shares of McKesson by 0.9% during the fourth quarter. IHT Wealth Management LLC now owns 1,196 shares of the company’s stock valued at $981,000 after purchasing an additional 11 shares during the period. LRI Investments LLC grew its holdings in shares of McKesson by 12.1% in the fourth quarter. LRI Investments LLC now owns 111 shares of the company’s stock worth $91,000 after purchasing an additional 12 shares during the last quarter. Finally, Macroview Investment Management LLC increased its stake in shares of McKesson by 3.9% in the fourth quarter. Macroview Investment Management LLC now owns 322 shares of the company’s stock worth $264,000 after buying an additional 12 shares during the period. Institutional investors own 85.07% of the company’s stock.

Insider Buying and Selling at McKesson

In related news, CEO Brian S. Tyler sold 8,463 shares of the business’s stock in a transaction dated Tuesday, July 7th. The shares were sold at an average price of $793.56, for a total transaction of $6,715,898.28. Following the sale, the chief executive officer owned 5,919 shares of the company’s stock, valued at $4,697,081.64. The trade was a 58.84% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Thomas L. Rodgers sold 2,388 shares of the company’s stock in a transaction dated Tuesday, May 26th. The stock was sold at an average price of $761.09, for a total transaction of $1,817,482.92. Following the completion of the sale, the executive vice president owned 3,090 shares in the company, valued at approximately $2,351,768.10. This trade represents a 43.59% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 28,748 shares of company stock valued at $22,262,035. Insiders own 0.06% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts recently commented on MCK shares. Barclays lowered their price target on shares of McKesson from $1,050.00 to $925.00 and set an “overweight” rating for the company in a report on Wednesday, June 10th. Deutsche Bank Aktiengesellschaft restated a “buy” rating and issued a $875.00 price objective on shares of McKesson in a research report on Friday, May 8th. TD Cowen lowered their price objective on shares of McKesson from $1,012.00 to $989.00 and set a “buy” rating for the company in a research note on Tuesday, July 21st. JPMorgan Chase & Co. dropped their target price on shares of McKesson from $1,107.00 to $1,015.00 and set an “overweight” rating for the company in a report on Friday, May 8th. Finally, UBS Group raised their target price on McKesson from $1,000.00 to $1,050.00 and gave the stock a “buy” rating in a research note on Friday, May 8th. Fourteen investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $962.67.

Key Headlines Impacting McKesson

Here are the key news stories impacting McKesson this week:

• Positive Sentiment: McKesson’s compounding growth remains the primary bullish catalyst. The company delivered strong fiscal 2026 results, raised its outlook, increased its dividend and expanded share repurchases. Its distribution and specialty-pharmaceutical businesses continue to generate substantial free cash flow, which may appeal to investors favoring defensive, cash-rich companies. McKesson’s Compounding Keeps Adding Up
• Neutral Sentiment: Wall Street is focused on estimates for McKesson’s quarter ended June 2026, including operating metrics beyond revenue and earnings. The estimates could influence expectations for the company’s upcoming report, but the article does not identify a new earnings surprise or change in guidance. Curious about McKesson Q1 Performance?
• Neutral Sentiment: Recent market commentary highlights a rotation toward defensive stocks as investors respond to inflation, geopolitical tension and uncertainty over interest rates. McKesson’s healthcare-distribution model and free-cash-flow generation could benefit from that trend, although the broader market backdrop remains unsettled. McKesson’s Compounding Keeps Adding Up
• Negative Sentiment: The latest reported quarter offered a mixed signal: adjusted earnings exceeded expectations, but revenue fell short of consensus despite year-over-year growth. That result, combined with a valuation near 22 times earnings and the absence of a fresh company-specific catalyst, may be encouraging profit-taking after the stock’s strong advance.

McKesson Stock Up 0.2%

MCK opened at $857.61 on Monday. McKesson Corporation has a 52 week low of $637.00 and a 52 week high of $999.00. The stock has a market cap of $100.41 billion, a PE ratio of 22.29, a PEG ratio of 1.41 and a beta of 0.31. The business has a 50 day moving average of $790.71 and a 200-day moving average of $840.33.

McKesson (NYSE:MCK) last issued its quarterly earnings results on Thursday, May 7th. The company reported $11.69 earnings per share for the quarter, topping the consensus estimate of $11.56 by $0.13. The company had revenue of $96.30 billion for the quarter, compared to analysts’ expectations of $101.35 billion. McKesson had a negative return on equity of 345.35% and a net margin of 1.18%.The firm’s revenue for the quarter was up 6.0% on a year-over-year basis. During the same period in the prior year, the firm earned $10.12 earnings per share. McKesson has set its FY 2027 guidance at 43.800-44.600 EPS. Equities analysts anticipate that McKesson Corporation will post 44.28 EPS for the current year.

McKesson Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Tuesday, September 1st will be paid a $0.94 dividend. This represents a $3.76 annualized dividend and a dividend yield of 0.4%. The ex-dividend date is Tuesday, September 1st. This is a positive change from McKesson’s previous quarterly dividend of $0.82. McKesson’s dividend payout ratio (DPR) is 9.77%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.